C4 Therapeutics, Inc. (CCCC): A Bull Case Theory
We came across a bullish thesis on C4 Therapeutics, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CCCC.
C4 Therapeutics Inc. (CCCC)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 9,439,328 | $18,029,116 | 0.02% | |
| 2. | RA Capital Management Peter Kolchinsky | 8,000,000 | $15,280,000 | 0.16% | |
| 3. | Lynx1 Capital Management Weston Nichols | 7,098,133 | $13,557,434 | 2.74% | |
| 4. | Soleus Capital Guy Levy | 3,803,942 | $7,265,529 | -47% | 0.27% |
| 5. | SilverArc Capital Devesh Gandhi | 1,994,224 | $3,808,968 | +6% | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.60 | 5,667 | $31,735.20 | 5,667 | 2023-02-08 | Filing | |
| $8.40 | 10,000 | $84,000.00 | 10,000 | 2022-04-12 | Filing | |
| $19.00 | 5,263 | $99,997.00 | 5,263 | 2020-10-06 | Filing | |
| $19.00 | 5,030 | $95,570.00 | 5,030 | 2020-10-06 | Filing | |
| $19.00 | 1,315 | $24,985.00 | 15,994 | 2020-10-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.22 | 10,000 | $22,200.00 | 156,382 | 2026-01-16 | Filing | |
| $3.15 | 669 | $2,107.35 | 107,805 | 2025-02-18 | Filing | |
| $3.15 | 490 | $1,543.50 | 110,842 | 2025-02-14 | Filing | |
| $32.66 | 1,054 | $34,420.48 | 15,000 | 2022-01-04 | Filing | |
| $31.59 | 13,946 | $440,547.17 | 16,054 | 2022-01-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,981,662 | $17,154,974 | 0% | |
| 2. | 7,171,910 | $13,698,348 | 1.05% | |
| 3. | 4,379,815 | $8,365,446 | 0% | |
| 4. | 4,344,918 | $8,298,793 | 0.05% | |
| 5. | 2,387,586 | $4,560,290 | 0% |
News See All
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts.
12 Best Biotech Penny Stocks To Invest In Now
Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from lower borrowing costs: biotechnology stocks.
10 Best Biotech Penny Stocks to Buy Now
In 2024, the healthcare industry has been doing well, encouraging investors to look into new and exciting opportunities.
Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Small Cap Growth Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
11 Hot Healthcare Stocks To Buy Now
In this article, we will be taking a look at 11 hot healthcare stocks to buy now.
12 Best High Risk Penny Stocks to Buy Now
Investors are jubilant over Nvidia crushing analyst estimates in its latest quarterly report.
Hedge Fund and Insider Trading News: Accendo Capital, Skye Capital, Vivaris Capital, ARR Investment Partners, C4 Therapeutics Inc (CCCC), and More
Stockholm (HedgeNordic) – Activist investor Accendo Capital has expanded its investment team by hiring Nicholas Bianco as a portfolio manager.
Is C4 Therapeutics, Inc. (CCCC) A Good Stock To Buy?
In this article we will analyze whether C4 Therapeutics, Inc.
Hedge Funds Are Piling Into C4 Therapeutics, Inc. (CCCC)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June.
Hedge Fund Resource Center Billionaire Hedge Funds
